RecruitingNCT06178120
Disease Progression in Women With X-linked Adrenoleukodystrophy
An Observational Study to Assess Disease Progression in Women With X-linked Adrenoleukodystrophy
Sponsor
Minoryx Therapeutics, S.L.
Enrollment
40 participants
Start Date
Jan 2, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Observational, single-site prospective and minimally interventional study in women with X-linked adrenoleukodystrophy (ALD), conducted in France.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria5
- Women aged 18 years old or older.
- Diagnosis of X-linked ALD based on genetic testing, altered VLCFA levels, or family history.
- Willing to undergo annual follow-up visits, including brain and spinal cord MRI scans.
- Provision of written informed consent.
- Affiliation or beneficiary of a French social security system or of such a regime.
Exclusion Criteria5
- Any condition that in the opinion of the investigator are likely to adversely affect the study participation, interfere with study compliance, or confound the study results.
- Under treatment or previous treatment with leriglitazone.
- Pregnant or lactating women.
- Subjects benefiting from laws aimed at protecting vulnerable adults: subjects being deprived of liberty by judicial or administrative decision, subjects under guardianship.
- Participation in an interventional clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06178120